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Early detection, including cancer screening and surveillance, is emerging as
one of the most important topics in modern oncology. Because symp-
tomatic presentation remains the predominant route to cancer diagnosis,
there is a growing interest in developing techniques to detect the disease at
an early, curative stage. Moreover, growing understanding of cancer biol-
ogy has paved the way for prevention studies with the focus on therapeutic
interventions for premalignant conditions. Where there is a recognisable
precursor stage, such as a colorectal adenoma or Barrett’s metaplasia, the
removal of abnormal tissue prevents the development of cancer and
enables stratification of the patient to a high-risk group requiring further
surveillance. Here, we provide a review of the available technologies for
early diagnosis and minimally-invasive treatment.
1. Introduction
Early detection, including cancer screening and surveil-
lance, is emerging as one of the most important topics
in modern oncology. Because symptomatic presenta-
tion remains the predominant route to cancer diagno-
sis, there is a growing interest in developing techniques
to detect the disease at an early, curative stage. More-
over, a growing understanding of cancer biology has
paved the way for prevention studies with the focus on
therapeutic interventions for premalignant conditions.
Where there is a recognisable precursor stage, such as
a colorectal adenoma or Barrett’s metaplasia, the
removal of abnormal tissue prevents the development
of cancer and enables stratification of the patient to a
high-risk group requiring further surveillance.
The two main ways of screening for early neoplasia
include imaging and molecular biomarker testing.
Gastrointestinal (GI) malignancies, including oesopha-
geal, stomach and bowel cancer, represent a group of
diseases where both of these approaches have been
extensively investigated. On the one hand, imaging for
GI malignancy is tractable given the accessibility of
the GI tract for imaging modalities including endo-
scopy. On the other hand, the high prevalence of GI
cancers raises the need for less invasive and more cost-
effective methods and some molecular biomarkers
have the potential to replace endoscopy as a screening
modality. The utility of biomarkers expands beyond
the primary detection to include monitoring of the
course of the disease, response to therapy and early
relapse detection after treatment. In this review, we
have used the GI tract as an example to present the
established and emerging screening methodologies for
early cancer detection and highlight the minimally-
invasive treatment options that are radically altering
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the rationale and health economics for early cancer
detection.
2. Technologies for early diagnosis
2.1. Endoscopy
2.1.1. Conventional endoscopy
Endoscopy with biopsies remain the gold standard for
the diagnosis of GI malignancies; however, its utility as
a screening modality is limited to colorectal cancer
(CRC). In 2015, 24 out of 28 countries in the European
Union had established or upcoming country-wide CRC
screening programmes targeting the average-risk popu-
lation, defined as individuals aged 50 years or older with
no additional risk factors (Navarro et al., 2017). Despite
the well-defined target population, there is a wide varia-
tion in screening practices among those countries result-
ing from different financial resources and healthcare
system capacities. The recommended strategies include
an annual or biennial faecal immunochemical test
(FIT), sigmoidoscopy every 5 years or colonoscopy
every 10 years. Endoscopic screening has the advantage
of facilitating CRC prevention by removal of the pre-
cursor lesion (ie, colorectal adenoma) at the time of the
initial examination. The first evidence suggesting that
sigmoidoscopy is effective in CRC screening, with bene-
fits lasting for up to ten years, comes from two case-con-
trolled studies performed in the early 1990s (Newcomb
et al., 1992; Selby et al., 1992). Further evidence from a
multicentre randomised controlled trial (RCT) showed
that a single flexible sigmoidoscopy, performed in
asymptomatic individuals aged 55–64 years, can reduce
CRC incidence and mortality by 23% [hazard
ratio = 0.77, 95% confidence interval (CI) = 0.70–0.84]
and 31% (hazard ratio = 0.69, 95% CI = 0.59–0.82),
respectively (Atkin et al., 2010). Sigmoidoscopy is a less
invasive test compared to colonoscopy; however, it only
examines the lower part of the large bowel, whereas
colonoscopy can visualise the entire colon. This is par-
ticularly important in the light of evidence for a proxi-
mal shift in the distribution of CRC (de Oliveira et al.,
2015). Therefore, colonoscopy is currently the preferred
CRC screening test in the US (Klabunde et al., 2011)
and several European countries (Zavoral et al., 2009),
although there is no high-quality data to support the
effectiveness of colonoscopy and its superiority over
other screening modalities. Three long-term RCTs are
currently underway and the results are highly awaited
(expected in 2020 and beyond). These trials include the
COLONPREV trial in Spain, comprising a non-infer-
iority trial comparing biennial FIT vs. one-time
colonoscopy (Quintero et al., 2012); the CONFIRM
trial in the US (ClinicalTrials.gov NCT01239082) com-
paring annual FIT vs. one-time colonoscopy; and the
NordICC trial in Northern and Eastern Europe
(Kaminski et al., 2012), a randomised trial comparing
once-only colonoscopy screening with no screening.
Oesophageal cancers, including oesophageal adeno-
carcinoma (OAC) and oesophageal squamous cell can-
cer (OSCC), have a relatively low incidence rate in the
Western world and, as a result, general endoscopic
screening has not been established. However, the rapidly
increasing incidence of OAC in recent decades has been
raised as a public health concern, especially in the UK,
where the incidence and mortality for this cancer are the
highest in Europe (Coleman et al., 2018). OAC is asso-
ciated with obesity and gastro-oesophageal reflux dis-
ease (GORD) and has a well-established precursor
condition, namely Barrett’s oesophagus, which is
defined as an endoscopically visible segment (≥1 cm) of
metaplastic columnar epithelium in the distal oesopha-
gus (Fitzgerald et al., 2014) (Fig. 1A). Although most
individuals with Barrett’s do not progress to adenocarci-
noma, the progression rate is 0.3% per annum and the
abysmal survival rate for OAC (unless detected at an
early stage) justifies early detection efforts (Desai et al.,
2012). Therefore, current guidelines from the British
Society of Gastroenterology recommend a targeted
screening approach, which involves a high-definition
white light endoscopy examination in high-risk individ-
uals. This is defined as patients with chronic GORD
symptoms and at least three of other risk factors: age
50 years or older, white race, male sex and obesity (this
threshold can be lowered for patients who have a first-
degree relative with Barrett’s oesophagus or OAC)
(Fitzgerald et al., 2014). This guideline is partly predi-
cated on the feasibility and affordability of large-scale
endoscopy given the low prevalence of the condition
estimated at around 2–3% of the population with reflux
symptoms (Ronkainen et al., 2005).
OSCC has a wide geographical variation, with inci-
dence rates up to 21.62 cases per 100 000 population in
certain high-incidence areas of China (Zeng et al.,
2016), Korea or Iran, where population-based screening
is a viable option. In Western countries, however, the
incidence of OSCC is low and continues to decline and
therefore, general screening is not recommended (Smyth
et al., 2017), with only high-risk individuals such as
patients after curative treatment for head and neck can-
cer, previous endoscopic resection of OSCC, caustic
injury, tylosis and achalasia benefiting from endoscopic
screening. By contrast to Barrett’s oesophagus, squa-
mous intraepithelial neoplasia (IEN), the precursor
lesion for OSCC, can be invisible on standard white-
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light imaging. Many advanced imaging techniques are
available to highlight areas with IEN, although the sim-
plest and most effective is Lugol’s iodine staining
(Codipilly et al., 2018). Dysplastic areas appear
unstained given the absence of glycogen in the neoplas-
tic cells (Fig. 1B) and several studies have shown that
Lugol’s dye staining increases the sensitivity for the
detection of high-grade IEN and early squamous cancer
(Dubuc et al., 2006; di Pietro et al., 2018).
Screening for gastric cancer is widely available in
countries with a high prevalence, such as China, Japan
and Korea. In Japan, for example, the initial screening
programme started in the 1960s and was based on
photofluorography, which was offered to all residents
aged 40 years and older. With time, endoscopy has
become the investigation of choice for mass screening
including several major Japanese cities. Similar to
other GI malignancies, a non-cardia gastric cancer
commonly develops through a number of premalignant
stages from chronic atrophic gastritis, by way of
intestinal metaplasia, to dysplasia and cancer. This
sequence, often triggered by Helicobacter pylori infec-
tion, is known as Correa’s cascade (Correa et al.,
1975). Endoscopy gives the opportunity to identify
both the premalignant stage and early neoplasia.
Although general screening for gastric cancer is not
justified in Western countries, patients with previously
recognised precancerous conditions require long-term
endoscopic surveillance (Dinis-Ribeiro et al., 2012).
The European guidelines recommend 3-yearly monitor-
ing for extensive atrophy and/or intestinal metaplasia in
the stomach (involving both the antrum and the gastric
body). Patients with dysplasia without an endoscopi-
cally visible lesion should be closely followed up, either
immediately and 6 to 12 months thereafter, or within
12 months, respectively, for those with high grade or
low-grade dysplasia (Dinis-Ribeiro et al., 2012). How-
ever clinically useful, these recommendations are based
mainly on expert opinions and not on randomised con-
trolled trials (Dinis-Ribeiro et al., 2012).
Gastric cancer is usually sporadic, although 1–3%
of these neoplasms arise on a background of inherited
cancer predisposition (Hansford et al., 2015). This
includes hereditary diffuse gastric cancer syndrome
(HDGCS) associated with a germline mutation in the
E-cadherin gene (CDH1). Carriers of this mutation
have a lifetime risk of gastric cancer reaching up to
80% (van der Post et al., 2015). Female carriers addi-
tionally have a risk of a lobular subtype of breast can-
cer ranging between 39% and 52% (Hansford et al.,
2015). Individuals with a confirmed CDH1 mutation
are recommended to undergo prophylactic gastrec-
tomy; however, endoscopic surveillance may be offered
to those opting not to have gastrectomy at the current
time, with CDH1 mutation variants of uncertain sig-
nificance and those that fulfill HDGC clinical criteria
without germline CDH1 mutations. Such surveillance
should be performed in experienced centres, with the
use of high-definition endoscopy equipped with
advanced imaging modalities within a dedicated ses-
sion of at least 30 min. Target biopsies from suspi-
cious areas (pale in appearance) and multiple random
biopsies from each segment of the stomach should be
taken (more than 30 samples per session) (van der Post
et al., 2015).
Similar surveillance programmes are available for
patients with genetic syndromes predisposing to col-
orectal cancer, such as Lynch syndrome (mutation in
one of the DNA mismatch repair genes) and familial
adenomatous polyposis (FAP; mutation in the APC
gene). For the former, the British guidelines recommend
a biennial colonic surveillance regime starting at the age
Fig. 1. Barrett’s oesophagus and squamous cell cancer of the oesophagus. (A) Endoscopic image of Barrett’s oesophagus visible as a
salmon-coloured metaplastic epithelium (columnar) replacing the normal bright-pink epithelium of the distal oesophagus (squamous).
(B) Endoscopic image of an early squamous cell carcinoma in the oesophagus visible as an unstained area after Lugol’s iodine staining
(asterisk). Patients provided their written consent for the images to be used for educational purposes.
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of 25 years (or 5 years less than the first cancer case in
the family, whichever is the earlier) and biennial upper
GI endoscopy in families where there are cases of gas-
tric cancer, commenced at age 50 years (Dunlop, 2002).
In FAP with documented APC gene mutations, surveil-
lance might be offered as a temporary measure for
those who wish to postpone the prophylactic colectomy
for personal reasons. In these cases, six-monthly flexible
sigmoidoscopy and annual colonoscopy can be an
option, although surgery should be strongly recom-
mended before the age of 25 years. Following colec-
tomy, the rectum must be kept under review at least
annually, as well as the anorectal cuff after restorative
proctocolectomy (Dunlop, 2002). Upper GI endoscopy
should also be undertaken in FAP to identify adenoma-
tous polyps and early cancers, usually within the duode-
num. A 3-yearly upper GI endoscopy is recommended
from the age of 30 years (Dunlop, 2002).
Overall, endoscopy is characterised by high accuracy
in cancer detection; however, it is an operator-depen-
dent procedure, with a miss rate of 9.4–11.3% upper
GI cancers (Menon and Trudgill, 2014; Pimenta-Melo
et al., 2016) and 1.8–9.0% CRCs (Singh et al., 2014).
Other downsides include invasiveness and high costs.
Therefore, several alternative screening modalities are
being proposed to overcome those limitations.
2.1.2. Transnasal endoscopy
For oesophagogastric screening, ultrathin transnasal
endoscopy (TNE) may be a promising alternative to
standard endoscopy. As a result of its small diameter of
only 6 mm, TNE is characterised by high tolerability
and improved cost-effectiveness (mainly because it does
not require sedation). In previous studies, TNE was pre-
ferred by 59–71% of patients compared to standard
endoscopy (Jobe et al., 2006; Shariff et al., 2012, 2016).
Unsedated TNE can be safely performed in a sitting
position within a primary care office (Peery et al., 2012).
Several studies on the utility of TNE for screening
for oesophageal cancer and precancerous conditions
have been conducted. Previous RCTs demonstrated
sensitivity for Barrett’s oesophagus diagnosis ranging
between 91% and 100%, and a sensitivity of 66.7–
100% (Shariff et al., 2016), respectively. These results
were sufficient to include unsedated TNE as an alter-
native approach for screening for this premalignant
condition by the American College of Gastroenterol-
ogy (Shaheen et al., 2016). Moreover, TNE may be a
safe and well-tolerable method for OSCC screening in
high-risk individuals. In previous studies including
patients after head and neck and hypopharyngeal can-
cer, who are at risk for a second cancer, TNE has
been shown to be a feasible and safe procedure with a
performance of cancer detection comparable to chro-
moendoscopy with Lugol’s staining (Arantes et al.,
2013; Wang et al., 2014).
There are some downsides of TNE to consider.
Investment is required in the hardware (some are por-
table and others not) and the operator needs to be a
highly trained endoscopist. It provides a lower quality
image and a smaller biopsy size, which may compro-
mise the histopathological assessment (i.e. the portable
version does not permit a biopsy to be taken). More
studies on TNE technology in a larger set of individu-
als are required to understand the utility of this device
as a screening modality for oesophagogastric cancer
and premalignant conditions.
2.1.3. Capsule endoscopy
The introduction of video capsule endoscopy (VCE) in
the early 2000s provided a novel minimally-invasive
approach to evaluate the small bowel. VCE has
become an important diagnostic tool in the manage-
ment of obscure GI bleeding; however, its utility has
been gradually expanding to include assessment of coe-
liac disease, small bowel tumours and hereditary poly-
posis syndromes. Recently, new models of endoscopic
capsules adapted for the evaluation of the oesophagus
(PillCamTM ESO; Given Imaging, Yokne’am Illit,
Israel) and colon (PillCamTM COLON; Given Imaging)
have been developed, opening a potential role for VCE
as a screening modality.
Colon VCE might be particularly useful in screening
patients who are unable to undergo colonoscopy (as an
alternative to CT colonography). In a prospective multi-
centre trial in a cohort of patients after incomplete colo-
noscopy, VCE could identify more polyps than CT
colonography and the complete colonic evaluation with
VCE was achieved in 98% of cases (Spada et al., 2015).
More recently, a second-generation colon VCE was
developed and evaluated in a prospective study on 74
patients after incomplete colonoscopy. VCE detected
significant polyps (size ≥ 6 mm or number ≥ 3) in 24%
of cases. Importantly, most of the polyps (86%) were
found in the right side of the colon, comprising seg-
ments that could not be visualised before as a result of
incomplete endoscopy (Baltes et al., 2018).
VCE has also been investigated for the evaluation of
oesophageal cancer and premalignant conditions. A
meta-analysis summarising nine studies on 618 patients
with chronic GORD have shown that VCE could diag-
nose Barrett’s oesophagus with a sensitivity of 77%
and a specificity of 86%, respectively (Bhardwaj et al.,
2009). Oesophageal VCE was found to be safe and
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had a high proportion of patient preferring this
method over standard endoscopy (Bhardwaj et al.,
2009). Its accuracy in OSCC detection, however,
appears to be less encouraging. In a prospective cohort
study on 68 patients at risk of OSCC secondary to a
previous head and neck neoplasia, the per-patient sen-
sitivity, specificity, positive and negative predictive val-
ues were 63%, 86%, 77% and 76%, compared to
conventional gastroscopy. These values have dropped
down to 61%, 86%, 77% and 73%, respectively, com-
pared to endoscopy with Lugol staining (Heresbach
et al., 2010).
Further studies are needed to understand the utility
of VCE as a screening tool for GI malignancy; how-
ever, high procedural costs and inability to take biop-
sies remain a limiting factor for this method.
2.2. Molecular biomarkers
2.2.1 Stool tests for CRC detection
Molecular biomarkers are starting to play an impor-
tant role in the detection and stratification of patients
with GI malignancies aided by the rapid improvement
and low cost of sequencing-based technologies. For
example, a biomarker test that has revolutionised
CRC screening in the last decades is the faecal occult
blood test (FOBT), which is currently the most widely
used screening modality for this cancer (Zavoral et al.,
2009). The two main types of FOBT include guaiac
FOBT (gFOBT) and the FIT for haemoglobin. The
former detects the pseudoperoxidase activity of the
haemoglobin, whereas FIT detects the presence of glo-
bin by immunochemical reactions (Tinmouth et al.,
2015). Although there are no controlled trials compar-
ing FIT and gFOBT, some observational studies indi-
cate that FIT increases the sensitivity for CRC
detection (Allison et al., 1996; Brenner and Tao, 2013;
Park et al., 2010; Parra-Blanco et al., 2010). More-
over, a meta-analysis reported better participation with
FIT than gFOBT (relative risk = 1.16, 95%
CI = 1.03–1.3) (Hassan et al., 2012).
FIT can detect both cancer and advanced adenomas
(usually defined as size ≥ 10 mm and/or villous com-
ponent > 20% and/or presence of high-grade dys-
plasia) with a variable accuracy depending on the type
of the test. According to a recent systematic review for
the US Preventive Services Task Force, FIT in a single
stool specimen has a sensitivity ranging between 73%
and 88% and a specificity of 90–96% in CRC detec-
tion (Lin et al., 2016). The sensitivity in detecting
advanced adenoma ranged from 22.2% to 40.3%
(Chen et al., 2018).
New tests, such as the multitarget stool DNA test,
combine both mutant and methylated DNA markers
and a standard FIT. This test might even further
increase the specificity for the detection of curable-
stage CRC and advanced adenomas, although this
comes at a cost of slightly lower specificity (Imperiale
et al., 2014).
2.2.2. Non-endoscopic cell collection devices coupled
with in vitro tests for diagnosis of Barrett’s and early
oesophageal cancer
Given the costs associated with endoscopy-based
screening modalities, there is increasing interest in
non-endoscopic cell collection devices (Lao-Sirieix
et al., 2009; Moinova et al., 2018). This technology
has been used previously in the context of OSCC
screening but has failed as a result of a reliance on
cytological assessment of atypia. The combination of
an effective cell collection device coupled with
biomarkers has proven more tractable for Barrett’s
oesophagus.
Most data are available for Cytosponge (MRC Can-
cer Cell Unit, Cambridge, UK), which is a non-endo-
scopic cell collection device that consists of a capsule
attached to a string (Fig. 2A). After swallowing the
device, the capsule coating disintegrates within 5 min
upon reaching the stomach, revealing a 3-cm spherical
mesh that is withdrawn by pulling the string. Follow-
ing its retrieval, the Cytosponge collects superficial
cells from the length of the oesophagus. The device
can be safely administered by a trained nurse in an
office setting. The utility of the Cytosponge has been
mainly focused on the early diagnosis of Barrett’s
metaplasia in the primary care setting; however, its
potential role in OSCC screening is also being evalu-
ated (OSCAR trial IRAS Project ID 155007).
Samples obtained from the Cytosponge can be
assayed for various disease biomarkers, including the
trefoil-factor 3 (TFF-3), which is highly specific to gob-
let cells, a histological landmark of Barrett’s (Fig. 2B)
(Lao-Sirieix et al., 2009). This biomarker coupled with
Cytosponge could diagnose this condition with a sensi-
tivity of 79.9% (95% CI = 76.4–83.0%) and a speci-
ficity of 92.4% (95% CI = 89.5–94.7%) in a
multicentre case–control study that included cases with
an inadequate sample on an intention-to-treat basis
(Ross-Innes et al., 2015). The sensitivity increased to
87.2% (95% CI = 83.0–90.6%) for segments of Bar-
rett’s > 3 cm in length. Methylation or miRNAs are
alternative biomarkers that could avoid the paraffin
embedding and manual pathology review steps
required for TFF-3 (Chettouh et al., 2017). Moreover,
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some potential biomarkers could stratify patients with
Barrett’s into low- and high-risk groups for malignant
progression using a combination of biomarkers includ-
ing TP53 (Moinova et al., 2018).
Screening with this device can be cost-effective as
shown in a recent microsimulation model. Cytosponge
coupled with endoscopic therapy in a cohort of 50-
year-old men with a history of GORD could provide a
19% reduction of incident OAC cases as compared to
17% for screening with endoscopy only. This benefit is
mostly empowered by higher acceptability and uptake
of the Cytosponge test compared to endoscopy (45%
vs. 23%) (Benaglia et al., 2013). In another report,
Cytosponge screening in GORD patients with a fol-
low-up endoscopic confirmation for positive cases
would reduce the screening costs by 27–29% compared
to endoscopic screening only (Heberle et al., 2017).
Importantly for implementation, Cytosponge is a
safe and well-tolerated procedure that can be widely
deployed in primary care. In a recent systematic review
of five prospective trials assessing its performance in
2418 patients with various oesophageal conditions, this
test was associated with favourable acceptability of a
median score of 6 points (IQR = 5.0–8.0) on the visual
analogue scale (VAS). This score was higher compared
to unsedated endoscopy (median 5.0, IQR = 3.0–7.0;
P < 0.001). There were only two adverse events related
to the device among all studies: a minor self-limiting
pharyngeal bleeding and one case of detachment
(< 1 : 2000). Almost all patients successfully swallowed
the Cytosponge (91.1%) (Januszewicz et al., 2018).
Taken together, Cytosponge coupled with TFF-3 is
promising for a wide-ranged screening; however, it still
requires randomised trial data to fully evaluate its
diagnostic yield, cost-effectiveness and safety profile.
This is currently underway in the BEST3 trial
(ISRCTN68382401), which is a randomised trial in
13 000 individuals in multiple UK primary care sites
(funded by Cancer Research UK) (Offman et al.,
2018).
2.3. Serum biomarkers
In an ideal scenario, an early detection biomarker
would be as non-invasive as possible and inform for a
variety of malignancies. Blood or breath sampling is
feasible, although the challenge is to obtain specific
sensitivity and specificity to abrogate false positives
requiring extensive imaging or other work-ups to find
cancer. Progress is being made in this area.
2.3.1. Serum pepsinogen, gastrin-17 and H. pylori
antibodies
A recent analysis from the USA showed that non-inva-
sive screening with serum pepsinogen may be a cost-
effective strategy to reduce gastric cancer mortality in
a high-risk population of actively smoking men aged
> 50 years (Yeh et al., 2016). This test is aimed to
identify individuals with atrophic gastritis and more
advanced premalignant conditions, such as intestinal
metaplasia and dysplasia. Serum pepsinogen and gas-
trin-17 (G-17) levels reflect the morphologic and func-
tional status of the stomach mucosa. Pepsinogen I is
secreted by chief and mucous neck cells in the fundic
glands, whereas pepsinogen II is secreted by the cells
in the pylorus. When atrophic changes develop in the
corpus, the level of pepsinogen I decreases, and
the level of pepsinogen II remains stable. Therefore,
the pepsinogen I/II ratio changes in a stepwise manner
and can be used to inform about the presence and
grade of atrophic gastritis. Recent studies have shown
Fig. 2. Cytosponge oesophageal cell collection device. (A) Cytosponge oesophageal cell collection device in a gelatin capsule (right) and
expanded (left). (B) Trefoil-factor 3 staining (209) from a patient with Barrett’s oesophagus showing columnar lined epithelium with goblet
cells (arrowheads). Courtesy of Dr Maria O’Donovan (Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust,
Cambridge, UK).
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that using a threshold of pepsinogen I level
≤ 70 lgL1 and a pepsinogen I/II ratio ≤ 3.0, this test
could identify gastric atrophy (with and without more
advanced precancerous lesions) with a sensitivity of
71% (95% CI = 59–82%) and specificity of 98% (95%
CI = 97–99%) (Burucoa et al., 2013). The serological
panel can be enriched with testing for H. pylori infec-
tion, which is the main driver for atrophic gastritis
and a class I carcinogen according to the WHO
(Vogiatzi et al., 2007). Helicobacter pylori serological
testing and subsequent eradication of the bacteria
could serve as an independent strategy for primary
gastric cancer prevention.
A recent multicentre prospective cohort study from
the Netherlands and Norway showed that the serologi-
cal panel (pepsinogen and G-17) might add additional
value in stratifying patients with premalignant condi-
tions of the stomach to those at higher and lower risk
for malignant progression (den Hollander et al., 2018).
Such stratification could lead to a reduction of unnec-
essary endoscopic surveillance in a large group of
patients with a low-risk profile. High-quality data from
randomised trials are needed to fully understand the
accuracy and cost-effectiveness of serum biomarker
testing. An ongoing multicentre RCT of H. pylori
eradication and pepsinogen testing for prevention of
gastric cancer mortality (the GISTAR Study) might
provide more information on the utility of this strategy
(Leja et al., 2017).
2.3.2. Circulating tumour DNA
The growing body of research on genetic alterations
responsible for tumour formation and progression
opened a new era of cancer detection and monitoring.
For almost every cancer, a specific somatic mutation
can be identified and potentially detected by the poly-
merase chain reaction-based technologies. By contrast
to well-established serum protein biomarkers, such as
the CEA or CA19-9, mutations present in the circulat-
ing tumour DNA (ctDNA) appear to be more specific
to the neoplastic tissue, which is advantageous for the
accuracy of this method.
In a landmark study by Bettegowda et al. (2014) on
640 patients with cancers originating from 14 different
tissue types, the specific ctDNA could be identified in
82% of solid tumours (outside the brain), although the
concentration of ctDNA varied significantly among
patients. Interestingly, CRC and gastro-oesophageal
cancers constituted a group with the highest fraction
of detectable ctDNA (Bettegowda et al., 2014).
Not surprisingly, the proportion of patients with
identifiable levels of ctDNA was increasing with the
disease stages, as 47% of patients with stage I disease
had detectable ctDNA, and 55%, 69%, and 82% with
stages II, III, and IV, respectively. For colorectal and
gastro-oesophageal cancers, all patients with advanced
disease had identifiable ctDNA and in 60–70% of
patients with localised disease. The ctDNA concentra-
tion was also shown to have a prognostic role, as its
increasing values were associated with decreasing sur-
vival rates (Bettegowda et al., 2014).
The utility of ctDNA was assessed in a separate
cohort of 206 patients with metastatic CRC based on
detecting mutations in the KRAS gene. This gene has
a significant clinical value as it determines the possibil-
ity of treatment with EGFR-inhibitors, such as panitu-
mumab or cetuximab. The test identified 69 patients
(33%) with detectable mutant KRAS genes in their
plasma (out of 79 patients with KRAS mutation pre-
sent in the tumour), which yielded a sensitivity of
87.2% with respect to cancer detection. Moreover, the
study provided promising evidence that the ctDNA
can also be used to detect a minimal residual disease
after treatment and predicting an early relapse (Bette-
gowda et al., 2014).
In a more recent study, a novel test called Cancer-
SEEK (a polymerase chain reaction-based assay) was
used to detect cell-free ctDNA in a cohort of 1005
patients with non-metastatic cancers of the ovary,
liver, stomach, pancreas, oesophagus, colorectum, lung
and breast (stages I to III) (Cohen et al., 2018). Nota-
bly, five of those cancers (i.e. ovary, liver, stomach,
pancreas, and oesophagus) are lacking wide-ranged
screening tests for the average-risk population. Cancer-
SEEK could detect those five cancers with a sensitivity
ranging from 69% to 98%. As before, the test showed
increasing accuracy in detecting more advanced stages
of the disease (sensitivity of 43%, 73% and 78% for
stages I, II and III, respectively).
Most importantly, the CancerSEEK test could over-
come the main limitation of ‘liquid-biopsy’ technolo-
gies, which is an inability to identify the primary
tumour site. This limitation arises from a fact that the
same driver gene mutations can be shared by multiple
cancer types. CancerSEEK used a combination of pro-
tein biomarkers and DNA mutations and, when cou-
pled with a supervised machine learning module, could
localise the source of cancer to two possible anatomic
sites in a median of 83% of patients, and to a single
organ in a median of 63% patients (Cohen et al.,
2018). However, further validation in large prospective
cohorts is required. This is especially important in view
of recent data showing that typical driver mutations
can occur in healthy cells throughout life, which does
not necessarily alter the cell behaviour. For example, a
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study analysing the oesophageal epithelium from
healthy donor samples showed the presence of TP53
mutations in 5–10% across all nine donors, with the
oldest donor (75 years old) having TP53 mutations in
20–35% of cells (Martincorena et al., 2018). In
another study, analysing the role of ctDNA in the
early detection of small-cell lung cancer, the TP53
mutations were present in the plasma of 11% of the
225 non-cancer controls (Fernandez-Cuesta et al.,
2016). Lastly, the KRAS cell-free DNA mutations
could be detected in 3.7% of healthy controls and in
4.3% of patients with chronic pancreatitis in a study
focused on pancreatic cancer detection (Calvez-Kelm
et al., 2016).
To overcome those potential limitations, the ctDNA
technology is constantly being refined. Recently, an
immunoprecipitation-based protocol was introduced,
where further genotyping of ctDNA is being con-
ducted to assess the tumour-specific methylation pat-
terns, which then can be detected in the plasma (Shen
et al., 2018). This approach has the potential to
improve the sensitivity and cost-effectiveness of
ctDNA technology; however, it is still on its very early
phases of implementation and the field is evolving
rapidly.
2.4. Breath tests
Electrical interfaces to measure the subtle volatile
organic compounds (VOC) profiles of different dis-
eases is a very attractive screening modality since it
can be performed in a primary care setting. VOC is a
carbon-containing compound that can be detected in
the gas phase at room temperature. Up to now, the
established role of VOC measurements includes
breathalysers for ethanol detection, carbon-13 urea test
for H. pylori infection and hydrogen-methane testing
for small-bowel bacterial overgrowth. Recently, the
analysis of VOCs within exhaled breath is being evalu-
ated as a novel approach to the diagnosis of cancer.
A meta-analysis of 63 studies on 3554 patients with
different cancer types (mostly lung, breast and gastro-
oesophageal) has shown a sensitivity of breath testing
for cancer diagnosis ranging from 28% to 100%, and
a specificity of 61–100%. The overall pooled analysis
showed a mean area under the receiver operating
characteristic (ROC) curve of 0.9, and a pooled sensi-
tivity and specificity of 79% (95% CI = 77–81%) and
89% (95% CI = 88–90%), respectively (Hanna et al.,
2018). The substantial heterogeneity between the stud-
ies, including different methods of sample collection
and test environment, remains a limitation of this
analysis.
Moreover, breath testing appears to have a role in
detecting premalignant disease. In a recent proof of
concept cross-sectional study using an e-nose device to
evaluate the breath VOCs in a cohort of patients with
dysplastic Barrett’s oesophagus (n = 122), the device
showed a sensitivity of 82%, a specificity of 80% and
an area under the curve of 0.79 (Chan et al., 2017) for
the diagnosis of this condition. A 95% enrolment rate
during the study indicated that this technique could be
widely acceptable (Chan et al., 2017).
A number of different mass spectrometry methods
are being evaluated which have the potential to dra-
matically improve the sensitivity. The ease of use
means that breath tests detecting VOCs have a poten-
tial role in mass screening, however, standardisation
and validation of this technique are required before
implementation into clinical practice.
2.5. Minimally-invasive treatment for early
neoplasia
Over the last two decades, minimally-invasive treat-
ment methodologies have revolutionised the therapy of
early neoplasia in the GI tract. Endoscopic resection
techniques have shifted a large proportion of patients
from invasive surgical treatment towards endoscopic
therapy, which is characterised by higher patient toler-
ability, a minimal complication rate and similar, if not
better, treatment outcomes. Moreover, endoscopic
therapy plays a key role in the treatment of premalig-
nant conditions, such as Barrett metaplasia or squa-
mous dysplasia of the oesophagus as well as adenomas
in the colon, making it one of the most important
tools in preventive medicine. Below, we highlight the
current and emerging minimally invasive treatment
modalities for GI premalignant conditions and early
cancers.
2.5.1. Ablative treatment
Ablative therapies have been utilised with increasing
frequency for the treatment of oesophageal premalig-
nant conditions, such as dysplastic Barrett’s oesopha-
gus and squamous dysplasia. Several modalities are
available for topical ablation, although argon plasma
coagulation (APC) and radiofrequency ablation (RFA)
remain the most commonly used. Ablative treatment is
particularly indicated in cases of low-grade dysplasia
(LGD) or high-grade dysplasia (HGD) without visible
abnormality (‘flat dysplasia’) when a focal resection
cannot be implemented. The aim of ablation is to
eradicate (burn) the dysplastic area and allow re-
epithelialisation with normal mucosa.
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Argon plasma coagulation involves the passage of
argon gas through an endoscopic catheter with the
conduction of monopolar current through the gas into
the tissue. It is a relatively cheap and widely available
ablation tool most commonly used to achieve
haemostasis in bleeding vessels within the GI tract.
However, the efficacy of APC in the treatment of dys-
plastic Barrett’s has also been demonstrated. The evi-
dence comes mainly from case series reports, and a
recent RCT showing that APC could achieve a clear-
ance of dysplasia in 83.8% cases and complete clear-
ance of Barrett’s metaplasia in 48.3% of the cases
(Farhad et al., 2018). Recently, APC has been com-
bined with a submucosal saline injection to improve its
safety (hybrid-APC) (Manner et al., 2016). The saline
injection creates a submucosal cushion that can lower
the risk of damaging the muscular layer of the oesoph-
agus (decreasing the post-procedural pain and risk of
perforation) and, additionally, it allows the use of a
higher energy setting, which improves the efficacy of
ablation.
On the other hand, RFA is an accepted and most
commonly used treatment modality for Barrett-related
neoplasia. This technique uses thermal energy to ablate
the superficial layers of the oesophageal lining to a
depth of approximately 1 mm. Two basic types of
RFA include RFA360 and RFA90. RFA360 consists
of a balloon with electrodes, which is insufflated within
the oesophageal lumen to deliver a shallow circumfer-
ential burn. Differently, RFA90 is used to focally burn
small areas of Barrett’s epithelium (Fig. 3). In many
countries, RFA has become the method of choice in
the treatment of dysplastic Barrett’s. In a landmark
multicentre sham-controlled trial by Shaheen et al.
(2009), a complete eradication of Barrett’s metaplasia
was achieved in 77.4% of patients and this has resulted
in lower disease progression rates (3.6% vs. 16.3%,
P = 0.03) and fewer cancers (1.2% vs. 9.3%,
P = 0.045) compared to the control group (sham proce-
dure). Overall, the efficacy in achieving complete remis-
sion for Barrett’s metaplasia after RFA treatment is
ranging between 75–88% and remission of dysplasia
between 88 and 92% (Haidry et al., 2013; Phoa et al.,
2014; Shaheen et al., 2009). The most recent follow-up
study shows that the response to the RFA treatment
can last up to 6 years (Klaver et al., 2018).
Some studies evaluated the efficacy of RFA in the
treatment of oesophageal squamous dysplasia. Two
prospective trials showed promising results with a
complete remission achieved in 87% and 97% of the
cases, respectively. However, the studies are limited by
a small cohort of patients and a short follow-up
(< 12 months) (Bergman et al., 2011; He et al., 2015).
An emerging concept in the treatment of oesopha-
geal premalignant disease is cryoablation. Although
this method has been used for decades in the treatment
of precancerous dermatologic and gynecologic condi-
tions, it has only been recently introduced for treat-
ment within the oesophagus. Cryoablation uses liquid
nitrogen at a temperature of 196 °C that is topically
applied through a low-pressure spray to the oesopha-
geal mucosa (Gosain et al., 2013). A newer modifica-
tion of this system employs a balloon that is inflated
in the oesophageal lumen and a nitrous oxide gas
spray is used to freeze target mucosa that is being in
contact with the balloon. In a prospective study with
41 patients with Barrett’s, a complete eradication of
dysplasia was achieved in 95% of individuals and com-
plete eradication of intestinal metaplasia in 88% of
patients, respectively, at 1 year after the procedure
(Canto et al., 2018). Cryoablation is a promising tool
in the treatment of premalignant conditions in the
oesophagus; however, larger randomised studies are
needed to fully understand its efficacy and safety.
2.5.2. Resection techniques
GI cancers at an early stage of disease, with a low risk
of lymph node metastases or distant spread, can be
managed endoscopically with comparable long-term
survival rates to surgery. This includes lesions limited
to the mucosa and the superficial layers of the submu-
cosa, which are the most amenable to endoscopic cure.
The two main resection techniques include endoscopic
mucosal resection (EMR) and submucosal dissection
(ESD). Indications for both EMR and ESD are con-
stantly expanding and generally include focal dysplas-
tic lesions in the oesophagus and the stomach, early
oesophageal cancers (T1a), early gastric cancers (T1a),
colonic polyps and early colorectal neoplasia.
Endoscopic mucosal resection offers both diagnostic
and therapeutic capability. It is typically used to resect
neoplastic lesions of less than 2 cm in size, or larger,
in a piece-meal fashion. There are several EMR tech-
niques. In injection-assisted EMR, the target lesion is
lifted with a submucosal injection of a fluid (typically
saline with epinephrine and indigo carmine dye) and
then resected with a cautery snare, comprising the
most commonly used method for the treatment of
polypoid lesions in the colon. In the oesophagus and
the stomach, however, a cap-assisted EMR is pre-
ferred. This technique uses a transparent suction cap
that is placed on the tip of the endoscope, with a pre-
opened snare at its distal edge. The target lesion is suc-
tioned into the cap and subsequently cut-off with the
cautery snare. Alternatively, a ligation EMR technique
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can be used, where a suction cap is equipped with rub-
ber bands that are deployed after suctioning the target
tissue into the cap. This creates a pseudo-polyp with
the neoplastic tissue included, which is then resected
with the snare beneath the base of the band.
Endoscopic mucosal resection provides histological
information including important prognostic factors
such as the degree of cancer differentiation, presence
or absence of lymphovascular invasion, depth of can-
cer invasion, and the distance of cancer from the deep
and lateral resection margins. These criteria determine
whether the curative intent of endoscopic treatment
was achieved. Lesions confined to the mucosa have a
very low rate of lymphatic involvement; therefore,
EMR is considered curative for most GI cancers lim-
ited to the mucosal layer (T1a) in conjunction with
low or moderate differentiation of cancer, no lympho-
vascular invasion and clear resection margins.
In some cancers, such as OAC, there is emerging
evidence that even with a presence of superficial
Fig. 3. Radiofrequency ablation for Barrett’s oesophagus. (A) Endoscopic image of the residual Barrett’s oesophagus epithelium (asterisks)
after previous endoscopic mucosal resection. (B) RFA90 device used for focal ablation of Barrett’s epithelium. Arrowhead shows the area of
single ablation with the RFA90 device. (C) Subsequent ablations are made to treat the whole remaining area of Barrett’s epithelium.
Patients provided written consent for the images to be used for educational purposes.
Fig. 4. Endoscopic submucosal dissection for early gastric cancer. Courtesy of Dr Massimiliano di Pietro (MRC Cancer Unit, University of
Cambridge, Cambridge, UK). (A) Endoscopic image of an early gastric cancer seen in white light imaging (arrowhead). (B, C) Advanced
imaging techniques, such as narrow-band imaging (B) and autofluorescence imaging (C) help to delineate the borders of the lesion. (D)
Marking around the lateral margins of the lesion using the tip of the endoscopic knife. (E, F) Circumferential cutting around the margins of
the lesion. (G, H) Dissection and removal of the whole specimen revealing the muscle layer (muscularis propria) of the gastric wall. Patients
provided written consent for the images to be used for educational purposes.
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submucosal invasion (less than 500 lm; T1b-Sm1),
with a good or moderate differentiation (G1/G2), no
lymphovascular invasion and clear resection margins,
can be safely managed endoscopically because a grow-
ing body of evidence supports a low risk of nodal
spread in this stage.
By contrast, the risk of nodal spread in OSCC is
much higher than in OAC and only cancers limited to
the top layers of the mucosa (m1 and m2) are consid-
ered safe in terms of endoscopic treatment (Cho et al.,
2014). The risk of nodal metastases in lesion penetrat-
ing into the deep mucosal layer (m3) and superficial
submucosal layers (Sm1) can be as high as 18% and
50%, respectively, according to some stusies (Cho
et al., 2014).
Endoscopic submucosal dissection (ESD) permits
en-bloc resection of larger lesions than with EMR.
Initially developed for gastric tumours, the utility of
ESD has expanded to include the treatment of oeso-
phageal and colorectal neoplasia. This procedure typi-
cally consists of several steps, including delineation
and marking around the lateral margins of the lesion,
injection of fluid underneath the target tissue, circum-
ferential cutting, dissection of the submucosal layer,
coagulation of visible vessels, and removal of the
resected specimen (Fig. 4). Currently, ESD is the
method of choice in the treatment of early gastric
cancers and OSCC. For oesophageal adenocarcino-
mas and early colorectal cancers, EMR still remains
the most commonly used technique in the Western
countries; however, ESD may be considered in
selected cases, such as for larger lesions (>2 cm),
poorly lifting lesions and lesions at increased risk for
submucosal invasion.
3. Conclusions
In recent decades, substantial progress has been made
in the field of early cancer detection and therapy. This
advancement can be readily appreciated for GI malig-
nancies, comprising one of the most prevalent group
of cancers globally. We are witnessing an increasing
trend where well-established invasive screening modali-
ties, such as endoscopic screening, are being increas-
ingly replaced by less invasive and biomarker-driven
tests. Endoscopic therapy, on the other hand, has
become the main treatment modality not only for
early cancers, but also for premalignant conditions of
the GI tract. Taken together, there is a real opportu-
nity to cause a significant shift in the stage of GI can-
cer diagnosis with an impact on population mortality
in the longer term, as well as a reduction in the mor-
bidity associated with cytotoxic- and surgical-based
treatments and expensive molecular targeted agents in
precision medicine. With ever increasing improvements
in early detection methods, we can expect this para-
digm to be increasingly applied for a variety of
cancers.
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